Guide to High-Sensitivity C-Reactive Protein (hsCRP)
Summary
High-sensitivity C-reactive protein (hsCRP) is a specialized blood test that measures even a very mild increase of C-reactive protein (CRP), an inflammatory marker produced by the liver in response to inflammation throughout the body.
Why It Matters
HsCRP serves as a valuable indicator of inflammation at levels too low to be detected by a standard CRP test, providing insights into cardiovascular health and chronic inflammatory conditions throughout the body.
When inflammation occurs anywhere in your body, your liver produces CRP as part of the immune response. While acute inflammation (from infection or injury) can cause CRP to rise dramatically, chronic low-grade inflammation leads to smaller, persistent elevations that may only be detectable with high-sensitivity testing. This low-grade inflammation plays a significant role in atherosclerosis, the process where plaque builds up in your arteries, and is linked to an increased risk of heart attacks and strokes.
See how the Levels Heart Health program can help lower your inflammation.
- Track hs-CRP alongside cardiovascular and metabolic markers
- Follow app-guided targets for fiber, saturated fat, and net carbs
- Retest hs-CRP and related markers in a Comprehensive panel
Get a free interpretation grounded in Levels biomarker expertise and informed by our dataset of over 1.5 billion health data points.
Upload your labs freeFree lab interpretation
Already have labs?
Get a free interpretation grounded in Levels biomarker expertise and informed by our dataset of over 1.5 billion health data points.
Upload your labs freeTransient elevations in CRP (often above 10 mg/L) are associated with recent infections, injuries, certain autoimmune disorders, or intense exercise and typically resolve within a few weeks, while chronic low-grade elevations (typically 1-10 mg/L) suggest ongoing inflammation that may indicate cardiovascular risk. To distinguish between these patterns, healthcare providers often recommend retesting after 2-3 weeks if your initial result is elevated and there's no obvious acute cause.
This marker is also an independent risk factor for cardiovascular disease, meaning it provides relevant information beyond traditional risk factors like cholesterol, blood pressure, and smoking. Elevated levels can also signal insulin resistance, metabolic syndrome, and risk of developing Type 2 diabetes. Additionally, an hsCRP test can help monitor inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease during periods of apparent remission.
Associated Symptoms
CRP levels themselves are laboratory findings rather than medical conditions. However, elevated levels may be associated with various inflammatory conditions, each with its own symptoms.
Common symptoms that may indicate conditions associated with elevated CRP:
- Fatigue: Persistent tiredness unrelieved by rest can be due to ongoing inflammatory processes
- Joint discomfort: Pain or stiffness, particularly in the morning, can result from inflammation in joint tissues
- Muscle complaints: Mild aches or weakness without an obvious cause can be related to systemic inflammation
- Cognitive changes: Mental fogginess or difficulty concentrating may result from inflammatory mediators affecting brain function
- Digestive issues: Bloating or irregular bowel habits can reflect inflammation in the digestive tract
- Skin manifestations: Rashes, dryness, or slow-healing wounds may be due to altered inflammatory responses
It's important to understand that low-grade inflammation (as detected by hsCRP) often produces no noticeable symptoms in its early stages, which is why testing can be valuable for detecting problems before they become symptomatic. Very low CRP levels (< 1 mg/L) generally indicate minimal inflammation and are associated with favorable long-term health outcomes.
Clinical Ranges
- Lab Reference Range: <1.0 (mg/L)
Lifestyle Factors That Can Impact It
Activities that may increase CRP levels include the following:
- High consumption of refined carbohydrates and sugars
- Trans fat and excessive saturated fat intake
- Sedentary lifestyle
- Smoking
- Alcohol consumption
- Chronic stress
- Obesity (particularly abdominal/visceral fat)
Activities associated with healthy CRP levels include the following:
- A Mediterranean diet rich in fruits, vegetables, whole grains, and olive oil
- Omega-3 fatty acid consumption (fatty fish, flaxseeds)
- Adequate sleep
Other Factors That Can Impact It
Medical Conditions
- Autoimmune disorders such as rheumatoid arthritis or lupus: Typically elevate CRP through systemic inflammation
- Sleep apnea: Raises CRP through intermittent hypoxia (inadequate oxygen supply) and stress hormones
- Metabolic syndrome: Increases CRP through multiple inflammatory pathways related to insulin resistance
Medications
- Statins: Reduce CRP independent of their cholesterol-lowering effects
- Vitamin E lowers CRP as well as some diabetes medications
- NSAIDs: May decrease CRP through their anti-inflammatory mechanisms
- Hormone replacement therapy: May increase CRP in some women
- Oral contraceptives: Can raise CRP
- Anti-inflammatory biologics for autoimmune conditions: Can dramatically lower CRP
- Some blood pressure medications, particularly ACE inhibitors and ARBs: May lower CRP
Testing Accuracy and Stability
HsCRP testing is highly sensitive and can be affected by various factors that may influence results, potentially making them less representative of your usual inflammatory status.
Factors That Can Affect the Accuracy of Your Test
- A recent illness or infection dramatically increases levels for 2--3 weeks, masking your baseline cardiovascular risk assessment.
- Minor injuries or dental procedures can elevate levels for several days, necessitating postponement of testing.
- Recent intense exercise can increase levels for 24--48 hours through muscle inflammation.
Research shows that for cardiovascular risk assessment, taking the average of two measurements 2--4 weeks apart provides more reliable results. This approach accounts for temporary fluctuations.
How it Relates to Other Markers
Your doctor will interpret hsCRP alongside other biomarkers and risk factors to get a more complete picture of your health status. Other tests may include:
- Low-density lipoprotein (LDL) cholesterol: When combined with hsCRP, LDL provides better risk prediction than either test alone.
- High-density lipoprotein (HDL) cholesterol: High HDL may partially offset the risk associated with elevated hsCRP.
- Blood pressure: Elevated hsCRP amplifies the cardiovascular risk from hypertension (high blood pressure).
- Triglycerides: Combined elevation of triglycerides (a type of fat in the blood) with hsCRP may suggest systemic inflammation.
- Hemoglobin A1C: Combined elevation of this marker (which measures average blood sugar over the past 2--3 months) with high hsCRP could indicate increased vascular risk in people with diabetes or prediabetes.
- Other inflammatory markers: Erythrocyte sedimentation rate (ESR), fibrinogen, and interleukin-6 (IL-6) can provide additional information about inflammation.
What Results May Mean in the Context of Other Markers
- High hsCRP with elevated LDL cholesterol: May indicate a substantially increased cardiovascular risk; a doctor may prescribe preventive measures.
- High hsCRP with normal cholesterol: "Residual inflammatory risk" may indicate increased cardiovascular risk, typically requiring attention despite normal lipids.
- High hsCRP with metabolic syndrome markers: Can indicate insulin resistance with an inflammatory component.
- Low hsCRP with elevated cholesterol: May indicate lower cardiovascular risk than suggested by cholesterol alone.
- Fluctuating hsCRP with stable other markers: May indicate other inflammatory processes or lifestyle factors affecting inflammation.
- Extremely high hsCRP (>10): Can suggest an active infection or inflammatory condition rather than cardiovascular risk.
Follow-up Considerations
If your CRP levels are elevated, your healthcare provider will develop a personalized approach that may include lifestyle modifications, closer monitoring of heart health, or medications targeting cholesterol and inflammation. This approach typically involves repeated testing to assess response to interventions and may include additional cardiovascular risk assessments. You should always speak to your doctor if you have medical questions or before making medical decisions.
When Re-Testing May be Appropriate
- Initial elevated value: Repeat in 2--4 weeks to confirm (due to natural variability)
- During lifestyle modifications: Every 3--6 months to assess impact
- On anti-inflammatory medications: Every 3--6 months to monitor effectiveness
- After acute illness: Wait at least 2--3 weeks before reassessing baseline
- Stable low risk: Consider annual testing alongside regular lipid panel
- Known cardiovascular disease: Every 3--6 months to monitor inflammation
Additional Testing Your Doctor May Consider
- Comprehensive lipid profile (including apolipoprotein measurements)
- Advanced cardiovascular testing (calcium score, carotid intima-media thickness, stress testing)
- Metabolic panel
- Evaluation for sleep apnea if suspected
- More comprehensive inflammatory markers in unclear cases
- Testing for specific inflammatory conditions if significantly elevated
When Additional Care May be Warranted
- Persistently elevated hsCRP (>3 mg/L) despite lifestyle changes
- Very high hsCRP (>10 mg/L) without obvious cause
- Rising hsCRP levels over time
- Elevated hsCRP with other concerning cardiovascular risk factors
- Elevated hsCRP with symptoms of cardiovascular disease
- Significantly elevated hsCRP with symptoms of inflammatory conditions
- Family history of premature cardiovascular disease with elevated hsCRP
Further Reading
What is hsCRP, and why does it matter?
Bibliography
References
1. Ridker, Paul M. "High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease." Circulation, vol. 103, no. 13, 2001, pp. 1813--1818. https://doi.org/10.1161/01.CIR.103.13.1813.
2. Pearson, Thomas A., et al. "Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice." Circulation, vol. 107, no. 3, 2003, pp. 499--511. https://doi.org/10.1161/01.CIR.0000052939.59093.45.
3. Ridker, Paul M., et al. "C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women." New England Journal of Medicine, vol. 342, no. 12, 2000, pp. 836--843. https://doi.org/10.1056/NEJM200003233421202.
4. Libby, Peter, et al. "Inflammation and Atherosclerosis." Circulation, vol. 105, no. 9, 2002, pp. 1135--1143. https://doi.org/10.1161/hc0902.104353.
5. Pepys, Mark B., and Gideon M. Hirschfield. "C-Reactive Protein: A Critical Update." Journal of Clinical Investigation, vol. 111, no. 12, 2003, pp. 1805--1812. https://doi.org/10.1172/JCI18921.
6. Kushner, Irving. "The Acute Phase Response: An Overview." Methods in Enzymology, vol. 163, 1988, pp. 373--383. https://doi.org/10.1016/0076-6879(88)63034-8.
7. Danesh, John, et al. "C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease." New England Journal of Medicine, vol. 350, no. 14, 2004, pp. 1387--1397. https://doi.org/10.1056/NEJMoa032804.
8. Kaptoge, Stephen, et al. "C-Reactive Protein Concentration and Risk of Coronary Heart Disease, Stroke, and Mortality: An Individual Participant Meta-Analysis." Lancet, vol. 375, no. 9709, 2010, pp. 132--140. https://doi.org/10.1016/S0140-6736(09)61717-7.
9. Nehring, Shannon M., et al. "C Reactive Protein." StatPearls, updated 10 Jul. 2023, StatPearls Publishing, 2025. https://www.ncbi.nlm.nih.gov/books/NBK441843/.
10. González, A., et al. "Metabolic Syndrome, Insulin Resistance and the Inflammation Markers C-Reactive Protein and Ferritin." European Journal of Clinical Nutrition, vol. 60, 2006, pp. 802--809. https://doi.org/10.1038/sj.ejcn.1602386.
11. den Engelsen, Clara, et al. "High-Sensitivity C-Reactive Protein to Detect Metabolic Syndrome in a Centrally Obese Population: A Cross-Sectional Analysis." Cardiovascular Diabetology, vol. 11, 2012, article 25. https://doi.org/10.1186/1475-2840-11-25.
12. Anan, Fumio, et al. "High-Sensitivity C-Reactive Protein is Associated with Insulin Resistance and Cardiovascular Autonomic Dysfunction in Type 2 Diabetic Patients." Metabolism, vol. 54, no. 4, 2005, pp. 552--558. https://doi.org/10.1016/j.metabol.2004.10.007.
13. Parrinello, Christina M., et al. "Six-Year Change in High-Sensitivity C-Reactive Protein and Risk of Diabetes, Cardiovascular Disease, and Mortality." American Heart Journal, vol. 170, no. 2, 2015, pp. 380--389. https://doi.org/10.1016/j.ahj.2015.04.016.
14. Chang, Seth, et al. "Disease Monitoring in Inflammatory Bowel Disease." World Journal of Gastroenterology, vol. 21, no. 40, 2015, pp. 11246--11259. https://doi.org/10.3748/wjg.v21.i40.11246.
15. Ridker, Paul M. "C-Reactive Protein: A Simple Test to Help Predict Risk of Heart Attack and Stroke." Circulation, vol. 108, no. 12, 2003, pp. e81--e85. https://doi.org/10.1161/01.CIR.0000093381.57779.67.
16. Huffman, Kelly M., et al. "Dietary Carbohydrate Intake and High-Sensitivity C-Reactive Protein in At-Risk Women and Men." American Heart Journal, vol. 154, no. 5, 2007, pp. 962--968. https://doi.org/10.1016/j.ahj.2007.06.027.
17. Liu, Simin, et al. "Relation Between a Diet with a High Glycemic Load and Plasma Concentrations of High-Sensitivity C-Reactive Protein in Middle-Aged Women." American Journal of Clinical Nutrition, vol. 75, no. 3, 2002, pp. 492--498. https://doi.org/10.1093/ajcn/75.3.492.
18. Mazidi, Mohsen, et al. "Inflammatory Markers Are Positively Associated with Serum Trans-Fatty Acids in an Adult American Population." Journal of Nutrition and Metabolism, 2017, article 3848201. https://doi.org/10.1155/2017/3848201.
19. Mazidi, Mohsen, et al. "Impact of the Dietary Fatty Acid Intake on C-Reactive Protein Levels in US Adults." Medicine (Baltimore), vol. 96, no. 7, 2017, article e5736. https://doi.org/10.1097/MD.0000000000005736.
20. Cederström, Stefan, et al. "Association Between High-Sensitivity C-Reactive Protein and Coronary Atherosclerosis in a General Middle-Aged Population." Scientific Reports, vol. 13, 2023, article 12171. https://doi.org/10.1038/s41598-023-38877-w.
21. Falconer, Carolyn L., et al. "Sedentary Time and Markers of Inflammation in People with Newly Diagnosed Type 2 Diabetes." Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 9, 2014, pp. 956--962. https://doi.org/10.1016/j.numecd.2014.03.009.
22. Tonstad, Serena, and Jill L. Cowan. "C-Reactive Protein as a Predictor of Disease in Smokers and Former Smokers: A Review." International Journal of Clinical Practice, vol. 63, no. 11, 2009, pp. 1634--1641. https://doi.org/10.1111/j.1742-1241.2009.02185.x.
23. Mangnus, L., et al. "Moderate Use of Alcohol is Associated with Lower Levels of C-Reactive Protein but Not with Less Severe Joint Inflammation: A Cross-Sectional Study in Early RA and Healthy Volunteers." RMD Open, vol. 4, 2018, article e000577. https://doi.org/10.1136/rmdopen-2017-000577.
24. Kennedy, Elizabeth, and Cara L. Niedzwiedz. "The Association of Anxiety and Stress-Related Disorders with C-Reactive Protein (CRP) within UK Biobank." Brain, Behavior, and Immunity - Health, vol. 19, 2021, article 100410. https://doi.org/10.1016/j.bbih.2021.100410.
25. Carpenter, Linda L., et al. "C-Reactive Protein, Early Life Stress, and Wellbeing in Healthy Adults." Acta Psychiatrica Scandinavica, vol. 126, no. 6, 2012, pp. 402--410. https://doi.org/10.1111/j.1600-0447.2012.01892.x.
26. Visser, Marjolein, et al. "Elevated C-Reactive Protein Levels in Overweight and Obese Adults." JAMA, vol. 282, no. 22, 1999, pp. 2131--2135. https://doi.org/10.1001/jama.282.22.2131.
27. Magno, M. S., et al. "Greater Adherence to a Mediterranean Diet is Associated with Lower C-Reactive Protein (CRP) Levels, but Not to Lower Odds of Having Dry Eye Disease." The Ocular Surface, vol. 30, 2023, pp. 196--203. https://doi.org/10.1016/j.jtos.2023.07.003.
28. Elisia, Ilaria, et al. "Omega-3 Supplementation Reduces C-Reactive Protein, Prostaglandin E2 and the Granulocyte/Lymphocyte Ratio in Heavy Smokers: An Open-Label Randomized Crossover Trial." Frontiers in Nutrition, vol. 9, 2022, article 1051418. https://doi.org/10.3389/fnut.2022.1051418.
29. Irwin, Michael R., et al. "Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation." Biological Psychiatry, vol. 80, no. 1, 2016, pp. 40--52. https://doi.org/10.1016/j.biopsych.2015.05.014.
30. Palmas, Walter, et al. "Antihypertensive Medications and C-Reactive Protein in the Multi-Ethnic Study of Atherosclerosis." American Journal of Hypertension, vol. 20, no. 3, 2007, pp. 233--241. https://doi.org/10.1016/j.amjhyper.2006.08.009.
31. Ramamoorthy, R. D., et al. "A Review of C-Reactive Protein: A Diagnostic Indicator in Periodontal Medicine." Journal of Pharmacy and Bioallied Sciences, vol. 4, suppl. 2, 2012, pp. S422--S426. https://doi.org/10.4103/0975-7406.100284.
32. Cerqueira, Érica, et al. "Inflammatory Effects of High and Moderate Intensity Exercise---A Systematic Review." Frontiers in Physiology, vol. 10, 2020, article 1550. https://doi.org/10.3389/fphys.2019.01550.
33. Mo, Jing, et al. "The Impact of the Cumulative Burden of LDL-C and hs-CRP on Cardiovascular Risk: A Prospective, Population-Based Study." Aging (Albany NY), vol. 12, no. 12, 2020, pp. 11990--12001. https://doi.org/10.18632/aging.103384.
34. Bilhorn, Katherine R., et al. "High-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Cardiovascular Disease in United States Adults." American Journal of Cardiology, vol. 110, no. 10, 2012, pp. 1464--1467. https://doi.org/10.1016/j.amjcard.2012.06.058.
35. Jiménez, Maria C., et al. "Association Between High-Sensitivity C-Reactive Protein and Total Stroke by Hypertensive Status Among Men." Journal of the American Heart Association, vol. 4, no. 9, 2015, article e002073. https://doi.org/10.1161/JAHA.115.002073.
36. Krishnamurthy, H. K., et al. "Association Between High-Sensitivity C-Reactive Protein (hs-CRP) Levels With Lipids and Micronutrients." Cureus, vol. 16, no. 8, 2024, article e67268. https://doi.org/10.7759/cureus.67268.
37. Reddy, K. S. S., et al. "Correlation Between Hemoglobin A1c (HbA1c) and High-Sensitivity C-Reactive Protein (hs-CRP) in Myocardial Infarction Patients and Their Six-Month Mortality Follow-Up." Cureus, vol. 16, no. 8, 2024, article e67070. https://doi.org/10.7759/cureus.67070.
38. Scheller, Jürgen, et al. "The Pro- and Anti-Inflammatory Properties of the Cytokine Interleukin-6." Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1813, no. 5, 2011, pp. 878--888. https://doi.org/10.1016/j.bbamcr.2011.01.034.
39. Nafari, A., et al. "High-Sensitivity C-Reactive Protein and Low-Density Lipoprotein Cholesterol Association with Incident of Cardiovascular Events: Isfahan Cohort Study." BMC Cardiovascular Disorders, vol. 22, 2022, article 241. https://doi.org/10.1186/s12872-022-02694-7.
40. Ridker, Paul M. "How Common Is Residual Inflammatory Risk?" Circulation Research, vol. 120, no. 4, 2017, pp. 617--619. https://doi.org/10.1161/CIRCRESAHA.117.310840.
41. Whelton, Steven P., et al. "Elevated High-Sensitivity C-Reactive Protein as a Risk Marker of the Attenuated Relationship Between Serum Cholesterol and Cardiovascular Events at Older Age: The ARIC Study." American Journal of Epidemiology, vol. 178, no. 7, 2013, pp. 1076--1084. https://doi.org/10.1093/aje/kwt007.
